Share on StockTwits

Agios Pharmaceuticals (NASDAQ:AGIO) COO John Duncan Higgons sold 13,000 shares of the stock on the open market in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $46.30, for a total transaction of $601,900.00. Following the completion of the sale, the chief operating officer now directly owns 169,835 shares in the company, valued at approximately $7,863,361. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Shares of Agios Pharmaceuticals (NASDAQ:AGIO) traded down 1.36% during mid-day trading on Wednesday, hitting $45.66. The stock had a trading volume of 383,648 shares. Agios Pharmaceuticals has a one year low of $15.77 and a one year high of $50.37. The stock’s 50-day moving average is $40.14 and its 200-day moving average is $39.93. The company’s market cap is $1.573 billion.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its earnings results on Thursday, August 7th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by $0.13. The company had revenue of $8.41 million for the quarter, compared to the consensus estimate of $11.00 million. During the same quarter in the previous year, the company posted ($2.80) earnings per share. The company’s revenue for the quarter was up 33.3% on a year-over-year basis. On average, analysts predict that Agios Pharmaceuticals will post $-1.94 earnings per share for the current fiscal year.

A number of research firms have recently commented on AGIO. Analysts at Citigroup Inc. initiated coverage on shares of Agios Pharmaceuticals in a research note on Tuesday, July 1st. They set a “buy” rating and a $58.00 price target on the stock. Analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Agios Pharmaceuticals in a research note on Monday, June 16th. They now have a $60.00 price target on the stock, up previously from $55.00.

Agios Pharmaceuticals, Inc is a biopharmaceutical company. The Company is intend to apply its deep understanding of metabolism, coupled with the Company’s ability to create medicines that can inhibit or activate metabolic enzymes, to fundamentally change the way cancer and inborn errors of metabolism (NASDAQ:AGIO) are treated.

Receive News & Ratings for Agios Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.